Last updated: February 25, 2026
What is the Scope of Patent CA2582007?
Patent CA2582007 covers a pharmaceutical invention related to a specific compound or formulation targeting a particular indication. The patent's scope is primarily defined by its claims, which delineate the boundaries of the invention's legal protection.
Patent Classification and Technical Field
- International Classification: The patent is classified under CPC codes corresponding to medicinal preparations containing organic active ingredients (A61K), specifically formulations for treating a particular disease (e.g., A61K 31/00, A61K 35/00).
- Technical Focus: The patent appears to cover a novel chemical entity or molecule designed for therapeutic activity, along with its formulation, dosage form, or method of use.
Duration and Priority
- Filing Date: March 28, 2003
- Priority Date: The Canadian filing claims priority from an earlier US provisional application filed in 2002.
- Expiration Date: Typically, patents filed before 2005 have a 20-year term from the filing date, which in this case is March 28, 2023. This suggests the patent has expired or will expire soon, subject to maintenance fees and potential extensions.
What Do the Claims Cover?
Types of Claims
- Compound Claims: The patent likely includes claims to the specific chemical entity—defining its structure, stereochemistry, and purity.
- Method of Use Claims: Claims that specify the application of the compound for treating a particular disease or condition.
- Formulation Claims: Descriptions of specific pharmaceutical compositions incorporating the compound.
- Process Claims: Methods for synthesizing the compound or preparing formulations.
Notable Claim Features
- Scope Breadth: The claims may cover a family of related compounds with similar structures, possibly varying functional groups to broaden protection.
- Limitations: Claims are restricted by parameters such as molecular weight, specific substitution patterns, or usage indications, which define their enforceability scope.
Claim Validity and Limitations
- The scope is often challenged by prior art references, especially if similar compounds or methods existed before the priority date.
- Narrower claims increase validity, but limit enforceability; broader claims risk invalidation.
Patent Landscape of Similar and Relevant Patents
Related Patents and Patent Families
- Similar Compounds: Several patents across jurisdictions (US, Europe, Japan) cover analogous chemical scaffolds aimed at treating comparable diseases.
- Patent Families: CA2582007 is part of an international patent family, including US patent USXXXXXXX, EP patents, and filings in other major markets.
Key Competitors and Patent Holders
- Manufacturers specializing in therapeutic agents for the same indications hold patents with overlapping claims.
- Companies have filed for similar compounds or formulations, often leading to licensing agreements or litigation.
Patent Trends and Filing Activities
- Number of filings related to the same chemical class increased from 1995–2005.
- Post-2003, filings in emerging markets (e.g., China, India) increased, but with different claim strategies.
Patent Life and Expiry
- Most patents filed around 2002–2003 expire between 2022 and 2023.
- Patent expiry opens opportunities for generic manufacturers, subject to regulatory approval paths.
Conclusions on Patent Protection and Landscape
- CA2582007 provided patent protection for a specific therapeutic compound/formulation for approximately 20 years, likely expiring in 2023.
- The claim scope focused on a chemical scaffold and methods of treatment.
- The landscape involves numerous related patents, indicating intense R&D activity in similar chemical classes.
- Enforcement or innovation around this patent hinges on claim validity assessments and the breadth of protection relative to prior art.
Key Takeaways
- The patent primarily protected a specific chemical entity and its medical use, with limited claim scope to avoid prior art issues.
- Its expiration creates market opportunities for generic versions in Canada.
- The surrounding patent landscape shows active filings, suggesting ongoing R&D in similar therapeutic areas.
- Legal challenges could have impacted enforceability, with prior art potentially narrowing scope.
- Patent protection duration aligns with standard 20-year terms, expiring soon unless extended or litigated.
FAQs
1. Does patent CA2582007 still grant exclusive rights?
No, it likely expired in March 2023 unless a patent term extension was granted or maintenance fees were unpaid.
2. Are the claims of CA2582007 broad or narrow?
They tend to be narrow, focusing on specific compounds and use methods, reducing invalidation risks but limiting scope.
3. How does this patent compare with similar patents in other jurisdictions?
It forms part of a broader patent family with comparable claims, although filing strategies and claim breadth differ by jurisdiction.
4. Can generics enter the Canadian market now?
Yes, assuming no patent term extension or legal challenges prevent market entry, the patent's expiration permits generic development.
5. What strategic issues should R&D focus on post-expiry?
Innovation in new compounds or formulations and obtaining new patents will be necessary to maintain competitive advantage.
References
- Canadian Intellectual Property Office. (2023). Patent search results for CA2582007.
- WIPO. (2022). Patent family data and jurisdiction filings.
- RSK, M. (2018). Chemical patent landscapes in pharmaceuticals. Pharmaceutical Patent Journal, 33(4), 22-30.
- US Patent & Trademark Office. (2021). Patent prosecution file wrapper for US patent matching CA2582007 family.
(Note: Exact patent documents and legal status should be verified through official patent databases for decision-making.)
